RxDoctor Payments DataLook up a doctor →

Barton Williams, MD

Family Medicine · Wilmington, NCNPI 1265540751

Payments from drug & device makers

$17,277,996in general payments, 2019–2025

Across 4,812 payments — averaging $3590.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$14.9M
  • Pfizer$1.6M
  • Johnson & Johnson$382K
  • Seqirus USA Inc$305K
  • AstraZeneca$27K
  • Janssen Research & Development, LLC$25K
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$300%
  • Speaking & faculty fees$1101%
  • Food & beverage$14,25499%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.3,663$14,933,750
Pfizer169$1,593,310
Johnson & Johnson26$381,627
Seqirus USA Inc100$305,090
AstraZeneca66$27,204
Janssen Research & Development, LLC4$25,040
Novo Nordisk121$1,699
Lilly USA, LLC78$1,045
AbbVie(2 entities)93$958
GSK37$829
Boehringer Ingelheim28$525
Abbott11$484
Sanofi-aventis U.S. LLC26$445
Amarin Pharma, Inc.25$393
Eisai Inc.50$361
Takeda Pharmaceuticals U.S.A., Inc.21$335
Merck29$328
Bausch Health US, LLC22$304
Kowa Pharmaceuticals America, Inc.24$300
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$281
Supernus Pharmaceuticals, Inc.6$257
Amgen(2 entities)15$244
Biohaven Pharmaceutical Holding Company Ltd.10$189
Exact Sciences11$178
Adlon Therapeutics L.p.11$175
Astellas Pharma US Inc12$169
Alkermes, Inc.7$130
Biohaven Pharmaceuticals, Inc.7$129
Idorsia Pharmaceuticals US Inc8$116
Novartis7$111
Sanofi1$110
Neos Therapeutics, LP7$96
Bayer6$95
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$89
Vanda Pharmaceuticals Inc.3$76
Protega Pharmaceutials Inc1$76
Antares Pharma, Inc.5$75
Arbor Pharmaceuticals, Inc.5$73
Hikma Pharmaceuticals USA4$71
Corium, LLC4$70
Esperion Therapeutics, Inc.5$66
Boston Scientific1$57
Teva Pharmaceuticals USA, Inc.4$51
VBI Vaccine (delaware) Inc.2$50
Azurity Pharmaceuticals, Inc.2$50
Aytu Biopharma, Inc.4$48
Davol Inc.2$47
Otsuka America Pharmaceutical, Inc.2$43
Sumitomo Pharma America, Inc.2$40
ARS Pharmaceuticals Operations, Inc.2$39
Shire North American Group Inc2$39
Daiichi Sankyo Inc.2$33
Phathom Pharmaceuticals, Inc.4$32
Sanofi Pasteur Inc.2$32
C2n Diagnostics, LLC1$32
Intra-sana Laboratories2$32
E.r. Squibb & Sons, L.L.C.2$32
Abiomed1$30
Mylan Specialty L.p.2$29
Assertio Therapeutics, Inc.2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,277,996 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$116,319
Medicare patients
462
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$69,701
JardianceEmpagliflozin46$50,761
EliquisApixaban42$38,108
FarxigaDapagliflozin Propanediol47$36,187
RybelsusSemaglutide22$33,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$28,825
MounjaroTirzepatide20$18,804
LinzessLinaclotide20$17,532
JanuviaSitagliptin Phosphate18$12,720
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$12,447
Synjardy XrEmpagliflozin/Metformin Hcl11$11,080
MyrbetriqMirabegron17$11,030
Breo ElliptaFluticasone/Vilanterol15$6,725
EdarbyclorAzilsartan Med/Chlorthalidone16$5,690
Amlodipine-ValsartanAmlodipine Besylate/Valsartan86$4,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,699$103,45076 claims
Boehringer IngelheimJardiance, Synjardy Xr$525$61,84157 claims
PfizerEliquis, Paxlovid$1,593,310$39,53757 claims
AstraZenecaFarxiga$27,204$36,18747 claims
GSKTrelegy Ellipta, Breo Ellipta$829$35,55043 claims
AbbVieLinzess, Synthroid$958$19,14035 claims
Lilly USA, LLCMounjaro$1,045$18,80420 claims
MerckJanuvia$328$12,72018 claims
Astellas Pharma US IncMyrbetriq$169$11,03017 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$73$5,69016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →